

BÖLÜM 72

İNCE BAĞIRSAK VE KOLONUN MALİGN NEOPLAZİLERİ

Gözde TAHTACI¹

İNCE BAĞIRSAK MALİGN NEOPLAZİLERİ

Epidemiyoloji

İnce bağırsak (İB), mide ve kolon arasında yer alır. Duodenum, jejunum ve ileum olmak üzere 3 kısımdan oluşur. Sindirim sistemi yüzey alanının yaklaşık %90'ını ince bağırsaklar oluşturmakta iken ince bağırsak kanserleri, gastrointestinal sistem (GIS) kanserlerinin yaklaşık %3'ünü oluşturmaktadır. Nedeni tam olarak saptanamamakla birlikte son yıllarda ince bağırsak kanserlerinin (İBK) insidansında artış saptanmaktadır. En sık görülen histolojik tipler nöroendokrin tümörler (NET), adenokarsinom, sarkom ve lenfomalardır. Adenokarsinomlar daha çok duodenumda, NET ise ileumda sık görülür. Sarkomlar ve lenfomalar tüm İB'da görülebilir. Ayrıca adenomlar, leiomyomlar, fibromlar ve lipomlar gibi benign tümörler de ince bağırsakta görülebilir.

Ortalama tanı yaşı 65 iken sarkomlar ve lenfomalar nispeten daha genç yaşta görülür. Erkeklerde kadınlara göre sıklığı biraz daha fazladır (E/K:1.3/1).

Etyoloji- Risk faktörleri

İBK'lerinin etyolojisi net olarak bilinmemekle beraber öne sürülen risk faktörleri şu şekilde sıralanabilir.

1. Herediter kanser sendromları

Familyal adenomatosis poliposis sendromu (FAP), herediter nonpoliposis kolon kanseri (HNPCC), Peutz-Jeghers Sendromu, MUT-HY-ilişkili poliposis (MAP) gibi herediter kanser sendromlarında İBK gelişim riski artmıştır.

2. Çölyak hastalığı

Otoimmün bir hastalık olan Çölyak hastalığında enteropati-ilişkili T-hücreli lenfoma

¹ Dr. Öğr. Üyesi, Gazi Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı Tıbbi Onkoloji BD., drgozdetahaci@gmail.com



KAYNAKLAR

1. Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, et al. *AJCC Cancer Staging Manual* (8th edition). Springer International Publishing: American Joint Commission on Cancer; 2017
2. André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. KEYNOTE-177 Investigators. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. *N Engl J Med*. 2020;383(23):2207-2218.
3. Baraniskin A, Buchberger B, Pox C, Holch JW, Schmiegel W, Heinemann V, et al. Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: a systematic review and meta-analysis. *Eur J Cancer*. 2019;106:37-44. 73.
4. Bauer RL, Palmer ML, Bauer AM, Nava HR, Douglass HO Jr. Adenocarcinoma of the small intestine: 21-year review of diagnosis, treatment, and prognosis. *Ann Surg Oncol*. 1994;1(3):183-8.
5. Chambers AJ, Pasieka JL, Dixon E, Rorstad O. Role of imaging in the preoperative staging of small bowel neuroendocrine tumors. *J Am Coll Surg*. 2010;211(5):620-7
6. Chung DC, Rustgi AK. The hereditary nonpolyposis colorectal cancer syndrome: genetics and clinical implications. *Ann Intern Med*. 2003;138(7):560-70
7. Chau I, Joulain F, Iqbal SU, Bridgewater JA. VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI. *BMC Cancer*. 2014;14:605.
8. Ecker BL, McMillan MT, Datta J, Mamtani R, Giantonio BJ, Dempsey DT, et al. Efficacy of adjuvant chemotherapy for small bowel adenocarcinoma: A propensity score-matched analysis. *Cancer*. 2016;122(5):693-701.
9. Fokas E, Allgäuer M, Polat B, Klautke G, Grabenbauer GG, Fietkau R, et al. German Rectal Cancer Study Group. Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12. *J Clin Oncol*. 2019;37(34):3212-3222
10. Gong J, Hutter C, Baron JA, Berndt S, Caan B, Campbell PT, et al. A pooled analysis of smoking and colorectal cancer: timing of exposure and interactions with environmental factors. *Cancer Epidemiol Biomarkers Prev*. 2012;21(11):1974-85.
11. Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. *Lancet Oncol*. 2014;15(10):1065-75.
12. Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. *Lancet Oncol*. 2012;13(6):579-88.
13. Howe JR, Cardona K, Fraker DL, Kebebew E, Untch BR, Wang YZ, et al. The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society. *Pancreas*. 2017;46(6):715-731.
14. Konishi T, Shimada Y, Hsu M, Tufts L, Jimenez-Rodriguez R, Cercek A, et al. Association of Preoperative and Postoperative Serum Carcinoembryonic Antigen and Colon Cancer Outcome. *JAMA Oncol*. 2018;4(3):309-315.
15. Lepage C, Bouvier AM, Manfredi S, Dancourt V, Faivre J. Incidence and management of primary malignant small bowel cancers: a well-defined French population study. *Am J Gastroenterol*. 2006;101(12):2826-32.
16. Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, et al; RECOURSE Study Group. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. *N Engl J Med*. 2015;372(20):1909-19.
17. McCarthy K, Pearson K, Fulton R, Hewitt J. Pre-operative chemoradiation for non-metastatic locally advanced rectal cancer. *Cochrane Database Syst Rev*. 2012;12:CD008368.
18. Moreno CC, Mittal PK, Sullivan PS, Rutherford R, Staley CA, Cardona K, et al. Colorectal Cancer Initial Diagnosis: Screening Colonoscopy, Diagnostic Colonoscopy, or Emergent Surgery, and Tumor Stage and Size at Initial Presentation. *Clin Colorectal Cancer*. 2016;15(1):67-73.
19. Ojha A, Zacherl J, Scheuba C, Jakesz R, Wenzl E. Primary small bowel malignancies: single-center results of three decades. *J Clin Gastroenterol*. 2000;30(3):289-93
20. Overman MJ, Varadhachary GR, Kopetz S, Adinin R, Lin E, Morris JS, et al. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. *J Clin Oncol*. 2009;27(16):2598-603.
21. Riihimäki M, Hemminki A, Sundquist J, Hemminki K. Patterns of metastasis in colon and rectal cancer. *Sci Rep*. 2016;6(1):29765.
22. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. *CA Cancer J Clin*. 2021;71(1):7-33.
23. Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, et al. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. *J Clin Oncol*. 2021;39(4):273-284.
24. Wu TJ, Yeh CN, Chao TC, Jan YY, Chen MF. Prognostic factors of primary small bowel adenocarcinoma: univariate and multivariate analysis. *World J Surg*. 2006;30(3):391-8.